Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial | Breast Cancer | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.212.130. Please contact the publisher to request reinstatement.
1.
Stampfer M, Colditz G. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.  Prev Med.1991;20:47-63.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1826173&dopt=AbstractGoogle Scholar
2.
Bush TL, Barrett-Connor E, Cowan LD.  et al.  Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program follow-up study.  Circulation.1987;75:1102-1109.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3568321&dopt=AbstractGoogle Scholar
3.
Grady D, Rueben SB, Pettiti DB.  et al.  Hormone therapy to prevent disease and prolong life in postmenopausal women.  Ann Intern Med.1992;117:1016-1037.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1443971&dopt=AbstractGoogle Scholar
4.
Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer.  Arch Intern Med.1991;151:67-72.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1824675&dopt=AbstractGoogle Scholar
5.
Steinberg KK, Thacker SB, Smith SJ.  et al.  A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer.  JAMA.1991;265:1985-1990.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1826136&dopt=AbstractGoogle Scholar
6.
Collaborative Group on Hormonal Factors in Breast Cancer.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer.  Lancet.1997;350:1047-1059.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10213546&dopt=AbstractGoogle Scholar
7.
The Women's Health Initiative Study Group.  Design of the Women's Health Initiative clinical trial and observational study.  Control Clin Trials.1998;19:61-109.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9492970&dopt=AbstractGoogle Scholar
8.
Writing Group for the Women's Health Initiative Investigators.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA.2002;288:321-333.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12117397&dopt=AbstractGoogle Scholar
9.
Hulley S, Grady D, Bush T.  et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.  JAMA.1998;280:605-613.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9718051&dopt=AbstractGoogle Scholar
10.
Hays J, Hunt JR, Hubbel A.  et al.  The Women's Health Initiative recruitment methods and results.  Ann Epidemiol.2003;13(9 suppl):S18-S77.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14575939&dopt=AbstractGoogle Scholar
11.
Grady D, Hulley SB, Furberg C. Venous thromboembolic events associated with hormone replacement therapy [letter].  JAMA.1997;278:477.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9256219&dopt=AbstractGoogle Scholar
12.
Anderson GL, Manson J, Wallace R.  et al.  Implementation of the Women's Health Initiative study design.  Ann Epidemiol.2003;13:S5-S17.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14575938&dopt=AbstractGoogle Scholar
13.
Curb D, McTiernan A, Heckbert SR.  et al.  Outcomes ascertainment and adjudication methods in the Women's Health Initiative.  Ann Epidemiol.2003;13(9 suppl):S122-S128.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14575944&dopt=AbstractGoogle Scholar
14.
Freedman LS, Anderson G, Kipnis V.  et al.  Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative.  Control Clin Trials.1996;17:509-525.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8974210&dopt=AbstractGoogle Scholar
15.
Cox DR. Regression analysis and life tables.  J R Stat Soc.1972;34:187-220.Google Scholar
16.
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials.  Biometrics.1979;35:549-446.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=497341&dopt=AbstractGoogle Scholar
17.
NIH/NHLBI News Release.  Statement from Barbara Alving, MD, Director of the Women's Health Initiative and Acting Director of the National Heart, Lung, and Blood Institute. Available at: http://www.nhlbi.nih.gov/new/press/04-03-02.htm. Accessed March 5, 2004.
18.
Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants.  Ann Epidemiol.2003;13(9 suppl):S78-S86.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14575940&dopt=AbstractGoogle Scholar
19.
Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992.  Obstet Gynecol.1995;85:6-10.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7800326&dopt=AbstractGoogle Scholar
20.
Herrington DM, Reboussin DM, Brosnihan KB.  et al.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis.  N Engl J Med.2000;343:522-529.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10954759&dopt=AbstractGoogle Scholar
21.
Waters DD, Alderman EL, Has J.  et al.  Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.  JAMA.2002;288:2432-2440.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12435256&dopt=AbstractGoogle Scholar
22.
Clarke SC, Kelleher J, Lloyd-Jones H.  et al.  A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study.  BJOG.2002;109:1056-1062.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12269682&dopt=AbstractGoogle Scholar
23.
ESPRIT Team.  Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial.  Lancet.2002;360:2001-2008.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12504395&dopt=AbstractGoogle Scholar
24.
Hodis HN, Mack WJ, Azen SP.  et al. for the Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group.  Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women.  N Engl J Med.2003;349:535-545.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12904518&dopt=AbstractGoogle Scholar
25.
Manson JE, Hsia J, Johnson KC.  et al.  Estrogen plus progestin and the risk of coronary heart disease.  N Engl J Med.2003;349:523-534.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12904517&dopt=AbstractGoogle Scholar
26.
Grady D, Herrington D, Bittner V.  et al. for the HERS Research Group.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).  JAMA.2002;288:49-57.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12090862&dopt=AbstractGoogle Scholar
27.
Wassertheil-Smoller S, Hendrix S, Limacher M.  et al.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.  JAMA.2003;289:2673-2684.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12771114&dopt=AbstractGoogle Scholar
28.
Simon JA, Hsia J, Cauley JA.  et al.  Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen/progestin Replacement Study (HERS).  Circulation.2001;103:638-642.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11156873&dopt=AbstractGoogle Scholar
29.
Viscoli CM, Brass LM, Kernan WN.  et al.  A clinical trial of estrogen-replacement therapy after ischemic stroke.  N Engl J Med.2001;345:1243-1249.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11680444&dopt=AbstractGoogle Scholar
30.
Prospective Studies Collaboration.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.  Lancet.2002;360:1903-1913.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12493255&dopt=AbstractGoogle Scholar
31.
Vasan RS, Larson MG, Leip EP.  et al.  Impact of high-normal blood pressure on the risk of cardiovascular disease.  N Engl J Med.2001;345:1291-1297.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11794147&dopt=AbstractGoogle Scholar
32.
Cauley JA, Robbins J, Chen Z.  et al.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.  JAMA.2003;290:1729-1738.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14519707&dopt=AbstractGoogle Scholar
33.
Cauley JA, Seeley DG, Ensrud K.  et al.  Estrogen replacement therapy and fractures in older women.  Ann Intern Med.1995;122:9-16.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7985914&dopt=AbstractGoogle Scholar
34.
Weiss NS, Ure CL, Ballard JH.  et al.  Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen.  N Engl J Med.1980;303:1195-1198.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7421945&dopt=AbstractGoogle Scholar
35.
Wells G, Tugwell P, Shea B.  et al.  Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women.  Endocrinol Rev.2002;23:529-539.Google Scholar
36.
Torgerson DJ, Bell-Seyer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials.  JAMA.2001;285:2891-2897.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11401611&dopt=AbstractGoogle Scholar
37.
Nelson HD, Humphrey LL, Nygren P.  et al.  Postmenopausal hormone replacement therapy.  JAMA.2002;288:872-881.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12186605&dopt=AbstractGoogle Scholar
38.
Chlebowski RT, Hendrix SL, Langer RD.  et al.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial.  JAMA.2003;289:3243-3253.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12824205&dopt=AbstractGoogle Scholar
39.
Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk.  J Natl Cancer Inst.2000;92:328-332.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10675382&dopt=AbstractGoogle Scholar
40.
Million Women Study Collaborators.  Breast cancer and hormone-replacement therapy in the Million Women Study.  Lancet.2003;362:419-427.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12927427&dopt=AbstractGoogle Scholar
41.
Li CI, Malone KE, Porter PL.  et al.  Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.  JAMA.2003;289:3254-3263.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12824206&dopt=AbstractGoogle Scholar
42.
Greendale GA, Reboussin BA, Sie A.  et al.  Effects of estrogen and estrogen-progestin on mammographic parenchymal density.  Ann Intern Med.1999;130:262-269.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10068383&dopt=AbstractGoogle Scholar
43.
Hsia J, Barad D, Margolis K.  et al. for the Women's Health Initiative Research Group.  Usefulness of prior hysterectomy as an independent predictor of Framingham risk score (the Women's Health Initiative).  Am J Cardiol.2003;92:264-269.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12888128&dopt=AbstractGoogle Scholar
44.
Hill DA, Weiss NS, LaCroix AZ. Adherence to postmenopausal hormone therapy during the year following the initial prescription: a population-based study.  Am J Obstet Gynecol.2000;182:270-276.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10694323&dopt=AbstractGoogle Scholar
45.
FDA News Release.  FDA updates hormone therapy information for postmenopausal women. February 10, 2004. Available at: http://www.fda.gov/bbs/topics/NEWS/2004/NEW01022.html. Accessed March 5, 2004.
Original Contribution
April 14, 2004

Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial

The Women's Health Initiative Steering Committee*
Author Affiliations

*Authors/WHI Steering Committee: Garnet L. Anderson, PhD (writing group chair, Fred Hutchinson Cancer Research Center, Seattle, Wash); Marian Limacher, MD (writing group cochair, University of Florida, Gainesville/Jacksonville). Members (in alphabetical order): Annlouise R. Assaf, PhD (Brown University, Providence, RI); Tamsen Bassford, MD (University of Arizona, Tucson/Phoenix); Shirley A. A. Beresford, PhD (Fred Hutchinson Cancer Research Center, Seattle); Henry Black, MD (Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill); Denise Bonds, MD (Wake Forest University School of Medicine, Winston-Salem, NC); Robert Brunner, PhD (University of Nevada, Reno); Robert Brzyski, MD (University of Texas Health Science Center, San Antonio); Bette Caan, DrPH (Kaiser Permanente Division of Research, Oakland, Calif); Rowan Chlebowski, MD (Harbor-UCLA Research and Education Institute, Torrance, Calif); David Curb, MD (University of Hawaii, Honolulu); Margery Gass, MD (University of Cincinnati, Cincinnati, Ohio); Jennifer Hays, PhD (Baylor College of Medicine, Houston, Tex); Gerardo Heiss, MD (University of North Carolina, Chapel Hill); Susan Hendrix, DO (Wayne State University School of Medicine/Hutzel Hospital, Detroit, Mich); Barbara V. Howard, PhD (MedStar Research Institute/Howard University, Washington, DC); Judith Hsia, MD (George Washington University Medical Center, Washington, DC); Allan Hubbell, MD (University of California at Irvine, Orange); Rebecca Jackson, MD (The Ohio State University, Columbus); Karen C. Johnson, MD (University of Tennessee, Memphis); Howard Judd, MD (University of California at Los Angeles); Jane Morley Kotchen, MD (Medical College of Wisconsin, Milwaukee); Lewis Kuller, MD (University of Pittsburgh, Pittsburgh, Pa); Andrea Z. LaCroix, PhD (Fred Hutchinson Cancer Research Center, Seattle); Dorothy Lane, MD (State University of New York at Stony Brook); Robert D. Langer, MD (University of California at San Diego, LaJolla/Chula Vista); Norman Lasser, MD (University of Medicine and Dentistry of New Jersey, Newark); Cora E. Lewis, MD (University of Alabama at Birmingham); JoAnn Manson, MD (Brigham and Women's Hospital, Harvard Medical School, Boston, Mass); Karen Margolis, MD (University of Minnesota, Minneapolis); Judith Ockene, PhD (University of Massachusetts/Fallon Clinic, Worcester); Mary Jo O'Sullivan, MD (University of Miami, Miami, Fla); Lawrence Phillips, MD (Emory University, Atlanta, Ga); Ross L. Prentice, PhD (Fred Hutchinson Cancer Research Center, Seattle); Cheryl Ritenbaugh, PhD (Kaiser Permanente Center for Health Research, Portland, Ore); John Robbins, MD (University of California at Davis, Sacramento); Jacques E. Rossouw, MD (National Heart, Lung, and Blood Institute, Bethesda, Md); Gloria Sarto, MD (University of Wisconsin, Madison); Marcia L. Stefanick, PhD (Stanford Prevention Research Center, Stanford University, Stanford, Calif); Linda Van Horn, PhD (Northwestern University, Chicago, Ill); Jean Wactawski-Wende, PhD (University at Buffalo, Buffalo, NY); Robert Wallace, MD (University of Iowa, Iowa City/Davenport); Sylvia Wassertheil-Smoller, PhD (Albert Einstein College of Medicine, Bronx, NY).

JAMA. 2004;291(14):1701-1712. doi:10.1001/jama.291.14.1701
Abstract

Context Despite decades of use and considerable research, the role of estrogen alone in preventing chronic diseases in postmenopausal women remains uncertain.

Objective To assess the effects on major disease incidence rates of the most commonly used postmenopausal hormone therapy in the United States.

Design, Setting, and Participants A randomized, double-blind, placebo-controlled disease prevention trial (the estrogen-alone component of the Women's Health Initiative [WHI]) conducted in 40 US clinical centers beginning in 1993. Enrolled were 10 739 postmenopausal women, aged 50-79 years, with prior hysterectomy, including 23% of minority race/ethnicity.

Intervention Women were randomly assigned to receive either 0.625 mg/d of conjugated equine estrogen (CEE) or placebo.

Main Outcome Measures The primary outcome was coronary heart disease (CHD) incidence (nonfatal myocardial infarction or CHD death). Invasive breast cancer incidence was the primary safety outcome. A global index of risks and benefits, including these primary outcomes plus stroke, pulmonary embolism (PE), colorectal cancer, hip fracture, and deaths from other causes, was used for summarizing overall effects.

Results In February 2004, after reviewing data through November 30, 2003, the National Institutes of Health (NIH) decided to end the intervention phase of the trial early. Estimated hazard ratios (HRs) (95% confidence intervals [CIs]) for CEE vs placebo for the major clinical outcomes available through February 29, 2004 (average follow-up 6.8 years), were: CHD, 0.91 (0.75-1.12) with 376 cases; breast cancer, 0.77 (0.59-1.01) with 218 cases; stroke, 1.39 (1.10-1.77) with 276 cases; PE, 1.34 (0.87-2.06) with 85 cases; colorectal cancer, 1.08 (0.75-1.55) with 119 cases; and hip fracture, 0.61 (0.41-0.91) with 102 cases. Corresponding results for composite outcomes were: total cardiovascular disease, 1.12 (1.01-1.24); total cancer, 0.93 (0.81-1.07); total fractures, 0.70 (0.63-0.79); total mortality, 1.04 (0.88-1.22), and the global index, 1.01 (0.91-1.12). For the outcomes significantly affected by CEE, there was an absolute excess risk of 12 additional strokes per 10 000 person-years and an absolute risk reduction of 6 fewer hip fractures per 10 000 person-years. The estimated excess risk for all monitored events in the global index was a nonsignificant 2 events per 10 000 person-years.

Conclusions The use of CEE increases the risk of stroke, decreases the risk of hip fracture, and does not affect CHD incidence in postmenopausal women with prior hysterectomy over an average of 6.8 years. A possible reduction in breast cancer risk requires further investigation. The burden of incident disease events was equivalent in the CEE and placebo groups, indicating no overall benefit. Thus, CEE should not be recommended for chronic disease prevention in postmenopausal women.

×